SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 22, 2003; DOI 10.1182/blood-2003-07-2512. This Article Full Text (PDF) All Versions of this Article: 2003-07-2512v1 103/4/1557    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Marr, K. A Articles by McDonald, G. B Search for Related Content PubMed PubMed Citation Articles by Marr, K. A Articles by McDonald, G. B Social Bookmarking                   What's this? Submitted July 25, 2003 Accepted September 9, 2003 Cyclophosphamide metabolism is impacted by azole antifungals Kieren A Marr*, Wendy Leisenring, Fulvio Crippa, John T Slattery, Lawrence Corey, Michael Boeckh, and George B McDonald Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA * Corresponding author; email: kmarr{at}fhcrc.org. We performed a randomized trial to compare the safety and efficacy of itraconazole to fluconazole in preventing fungal infections in allogeneic SCT patients. Itraconazole (intravenous 200 mg daily, or oral solution 2.5 mg/kg three times daily) and fluconazole (intravenous or oral, 400 mg daily) were administered with start of conditioning therapy, until at least 120 days after SCT. After enrollment of the first 197 patients, a data and safety monitoring board was convened to review potential drug-related toxicities. Patients who received itraconazole developed higher serum bilirubin and creatinine values in the first 20 days after SCT, with highest values in patients who received itraconazole concurrent with cyclophosphamide (CY) conditioning. Analysis of CY metabolism in a subset of patients demonstrated higher exposure to toxic metabolites among itraconazole compared to fluconazole recipients. These data suggest that azole antifungals, through differential inhibition of hepatic cytochrome P450 isoenzymes, impact CY metabolism and conditioning-related toxicities. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Michallet and J. I. Ito Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation J. Clin. Oncol., July 10, 2009; 27(20): 3398 - 3409. [Abstract] [Full Text] [PDF] O. A. Cornely, A. Bohme, D. Buchheidt, H. Einsele, W. J. Heinz, M. Karthaus, S. W. Krause, W. Kruger, G. Maschmeyer, O. Penack, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology Haematologica, January 1, 2009; 94(1): 113 - 122. [Abstract] [Full Text] [PDF] R. B Ibrahim, M. H Abidi, L. J Ayash, S. M Cronin, C. Cadotte, J. Mulawa, P. A Jacobson, D. W Smith, J. P Uberti, and D. J Edwards Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 113 - 121. [Abstract] [PDF] C. C. Blyth, P. Palasanthiran, and T. A. O'Brien Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review Pediatrics, April 1, 2007; 119(4): 772 - 784. [Abstract] [Full Text] [PDF] B. J. Hoeben, D. S. Burgess, J. T. McConville, L. K. Najvar, R. L. Talbert, J. I. Peters, N. P. Wiederhold, B. L. Frei, J. R. Graybill, R. Bocanegra, et al. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1552 - 1554. [Abstract] [Full Text] [PDF] A. Glasmacher, O. Cornely, A. J. Ullmann, U. Wedding, H. Bodenstein, H. Wandt, C. Boewer, R. Pasold, H.-H. Wolf, M. Hanel, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia J. Antimicrob. Chemother., February 1, 2006; 57(2): 317 - 325. [Abstract] [Full Text] [PDF] W. H. Kruger, J. Bohlius, O. A. Cornely, H. Einsele, H. Hebart, G. Massenkeil, S. Schuttrumpf, G. Silling, A. J. Ullmann, D. T. Waldschmidt, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology Ann. Onc., August 1, 2005; 16(8): 1381 - 1390. [Abstract] [Full Text] [PDF] M. Bornhauser, S. Pursche, M. Bonin, J. Freiberg-Richter, A. Jenke, T. Illmer, G. Ehninger, and E. Schleyer Elimination of Imatinib Mesylate and Its Metabolite N-Desmethyl-Imatinib J. Clin. Oncol., June 1, 2005; 23(16): 3855 - 3856. [Full Text] [PDF] B. Peng and R. Capdeville In Reply: J. Clin. Oncol., June 1, 2005; 23(16): 3857 - 3858. [Full Text] [PDF] N. Singh and D. L. Paterson Aspergillus Infections in Transplant Recipients Clin. Microbiol. Rev., January 1, 2005; 18(1): 44 - 69. [Abstract] [Full Text] [PDF] D. J. Winston, C. Emmanouilides, K. Bartoni, G. J. Schiller, R. Paquette, M. C. Territo, K. A. Marr, and M. Boeckh Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment Blood, September 1, 2004; 104(5): 1581 - 1582. [Full Text] [PDF] K. A. Marr, F. Crippa, W. Leisenring, M. Hoyle, M. Boeckh, S. A. Balajee, W. G. Nichols, B. Musher, and L. Corey Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood, February 15, 2004; 103(4): 1527 - 1533. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020